ADC Therapeutics (ADCT) Invested Capital (2019 - 2026)

ADC Therapeutics (ADCT) has reported Invested Capital for 7 consecutive years, with $4.6 million the latest figure, recorded in Q1 2026.

• Quarterly Invested Capital changed N/A year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (changed N/A YoY) and the FY2025 annual result came in at $3.0 million, changed N/A from the prior year.
• Invested Capital climbed to $4.6 million in Q1 2026 per ADCT's latest filing, from $3.0 million in the prior quarter.
• Over the last five years, Invested Capital for ADCT reached as high as $426.8 million in Q4 2022 and fell as low as $3.0 million in Q4 2025.
• A 4-year average of $103.1 million and a median of $120.0 million in 2022 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2022 — Invested Capital slipped 1.08% — and 2023, when it soared 1732.34%.
• Year by year, Invested Capital stood at $426.8 million in 2022, then sank by 71.89% to $120.0 million in 2023, then plunged by 97.5% to $3.0 million in 2025, then surged by 54.5% to $4.6 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $4.6 million, $3.0 million, and $120.0 million for Q1 2026, Q4 2025, and Q3 2023 respectively.